ISDA: 2I03

Deposition Date 2006-08-09

Release Date 2006-12-12

Last Version Date 2024-11-13

Entry Detail

PDB ID:

2I03

Keywords:

HYDROLASE

Title:

Crystal structure of human dipeptidyl peptidase 4 (DPP IV) with potent alkynyl cyanopyrrolidine (ABT-279)

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.40 Å

R-Value Free:

0.24

R-Value Work:

0.17

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Dipeptidyl peptidase 4
Gene (Uniprot):DPP4
Chain IDs:A, B, C, D
Chain Length:726
Number of Molecules:4
Biological Source:Homo sapiens

UniProt ID:P27487 Pfam ID:PF00930, PF00326 EC:3.4.14.5

Ligand Molecules

AXD

Primary Citation

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

Madar, D.J, Kopecka, H, Pireh, D, Yong, H, Pei, Z, Li, X, Wiedeman, P.E, Djuric, S.W, Von Geldern, T.W, Fickes, M.G, Bhagavatula, L, McDermott, T, Wittenberger, S, Richards, S.J, Longenecker, K.L, Stewart, K.D, Lubben, T.H, Ballaron, S.J, Stashko, M.A, Long, M.A, Wells, H, Zinker, B.A, Mika, A.K, Beno, D.W, Kempf-Grote, A.J, Polakowski, J, Segreti, J, Reinhart, G.A, Fryer, R.M, Sham, H.L, Trevillyan, J.M.Show

J.Med.Chem. 49 6416 6420 (2006)

PMID: 17034148 DOI: 10.1021/jm060777o

Abstact

Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes. Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9. Further modification led to an extremely potent (Ki(DPP)(-)(IV) = 1.0 nM) and selective (Ki(DPP8) > 30 microM; Ki(DPP9) > 30 microM) clinical candidate, ABT-279, that is orally available, efficacious, and remarkably safe in preclinical safety studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form